JP2013540748A - 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法 - Google Patents

血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法 Download PDF

Info

Publication number
JP2013540748A
JP2013540748A JP2013529362A JP2013529362A JP2013540748A JP 2013540748 A JP2013540748 A JP 2013540748A JP 2013529362 A JP2013529362 A JP 2013529362A JP 2013529362 A JP2013529362 A JP 2013529362A JP 2013540748 A JP2013540748 A JP 2013540748A
Authority
JP
Japan
Prior art keywords
adenosine
disease
adenosine receptor
hours
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013529362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540748A5 (https=
Inventor
マーガレット エス． バイノエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2013540748A publication Critical patent/JP2013540748A/ja
Publication of JP2013540748A5 publication Critical patent/JP2013540748A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013529362A 2010-09-16 2011-09-16 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法 Pending JP2013540748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38362810P 2010-09-16 2010-09-16
US61/383,628 2010-09-16
PCT/US2011/051935 WO2012037457A1 (en) 2010-09-16 2011-09-16 Use of adenosine receptor signaling to modulate permeability of blood-brain barrier

Publications (2)

Publication Number Publication Date
JP2013540748A true JP2013540748A (ja) 2013-11-07
JP2013540748A5 JP2013540748A5 (https=) 2014-10-30

Family

ID=45831982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529362A Pending JP2013540748A (ja) 2010-09-16 2011-09-16 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法

Country Status (5)

Country Link
US (1) US20130224110A1 (https=)
EP (1) EP2616538A4 (https=)
JP (1) JP2013540748A (https=)
CN (1) CN103221535A (https=)
WO (1) WO2012037457A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529325A (ja) * 2014-08-13 2017-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
JP2022545763A (ja) * 2019-06-21 2022-10-31 アカデミー オブ ミリタリー メディカル サイエンシズ Ａ２ａアデノシン受容体アゴニスト活性を有する２－ベンジリデンヒドラジノアデノシン化合物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
CA2875348A1 (en) * 2012-06-01 2013-12-05 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10092591B2 (en) * 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10953015B2 (en) 2016-02-03 2021-03-23 Cornell University Use of adenosine receptor signaling to regulate P-gp function
WO2017189849A1 (en) * 2016-04-27 2017-11-02 Immunicom, Inc. Nanoparticle compositions comprising adenosine receptor antagonists and methods of use
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
AU2018258654B2 (en) 2017-04-27 2022-01-06 The Johns Hopkins University Dendrimer compositions for use in angiography
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
EP3707193A1 (en) 2017-11-10 2020-09-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019109077A1 (en) 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
EP3988100A4 (en) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF AND USE
CN111789950A (zh) * 2019-10-15 2020-10-20 浙江大学 调控恐惧记忆巩固的方法和药物组合物
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
EP4431524A3 (en) 2019-12-04 2024-12-18 The Board Of Trustees Of The Leland Stanford Junior University Enhancing blood-brain barrier drug transport by targeting endogenous regulators
EP4216952A4 (en) * 2020-09-24 2024-11-20 NFlection Therapeutics, Inc. TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide
JP2024536844A (ja) * 2021-09-25 2024-10-08 ヌタリア リミテッド 処置様式のための標的封入戦略
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN116359519B (zh) * 2023-05-29 2023-09-15 中国人民解放军军事科学院军事医学研究院 CLDN5蛋白、Cldn5基因及其修饰在抑郁障碍诊断和/或治疗中的应用
CN117298087A (zh) * 2023-10-17 2023-12-29 张岳峰 促血液药物颅内转运合剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002284700A (ja) * 1989-09-27 2002-10-03 Elan Pharmaceuticals Inc 血液脳関門のモデル
WO2009114533A2 (en) * 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
GB9323884D0 (en) * 1993-11-19 1994-01-05 Eisai London Res Lab Ltd Physiological modulation
MXPA02001882A (es) * 1999-08-23 2002-08-20 Univ Tulane Modulacion del transportador de leptina a traves de la barrera hemato-encefalica.
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
GB0120124D0 (en) * 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
CN1791669A (zh) * 2002-06-20 2006-06-21 惠氏公司 用于预测血脑屏障通透性的方法和组合物
US20070032450A1 (en) * 2005-08-02 2007-02-08 Rieger Jayson M New compositions and methods for the treatment of inflammation
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
UY31631A1 (es) * 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002284700A (ja) * 1989-09-27 2002-10-03 Elan Pharmaceuticals Inc 血液脳関門のモデル
WO2009114533A2 (en) * 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6015033161; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．３８７，Ｎｏ．１, 20001103, ｐｐ．１０１-１０５ *
JPN6015033163; Ｎａｕｎｙｎ-Ｓｃｈｍｉｅｄｅｂｅｒｇｅ'ｓ　Ａｒｃｈ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．３７０，Ｎｏ．６, 200412, ｐｐ．４９２-４９９ *
JPN6015033165; 日本呼吸器学会雑誌 Ｖｏｌ．３６，Ｎｏ．３, 199803, ｐｐ．２３１-２３５ *
JPN6015033168; Ｂｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．１２９，Ｎｏ．５, 200003, ｐｐ．８７１-８７６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529325A (ja) * 2014-08-13 2017-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
JP2022545763A (ja) * 2019-06-21 2022-10-31 アカデミー オブ ミリタリー メディカル サイエンシズ Ａ２ａアデノシン受容体アゴニスト活性を有する２－ベンジリデンヒドラジノアデノシン化合物

Also Published As

Publication number Publication date
CN103221535A (zh) 2013-07-24
US20130224110A1 (en) 2013-08-29
EP2616538A1 (en) 2013-07-24
EP2616538A4 (en) 2014-03-05
WO2012037457A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
JP2013540748A (ja) 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
US20110262442A1 (en) Compositions for treating cns disorders
CN102014959B (zh) 血脑屏障通透性的调节
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
Mirzaa et al. Mutations in CENPE define a novel kinetochore-centromeric mechanism for microcephalic primordial dwarfism
US20220090021A1 (en) In vitro human blood brain barrier
Kaur et al. Role of tau in various tauopathies, treatment approaches, and emerging role of nanotechnology in neurodegenerative disorders
KR20190051967A (ko) 폴리글루타메이트화 항엽산 및 이의 용도
WO2006020145A2 (en) Flt3 inhibitors for immune suppression
AU2015221860B2 (en) TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
JP2004532809A (ja) ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
TW201803893A (zh) TATκ-CDKL5融合蛋白、其組成物、配製物及用途
ES2655291T3 (es) Uso de cladribina para tratar neuromielitis óptica
Kim et al. Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A
JP6997800B2 (ja) 神経炎症性障害の処置に使用される小有機分子
ES2614826T3 (es) Modulación de la permeabilidad de la barrera hematoencefálica
US20180318379A1 (en) Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
EP3226883B1 (en) Compositions for treatment of retinal degenerative diseases
KR102388363B1 (ko) 알츠하이머병（ａｄ）의 치료 및 예방
JP2020527558A (ja) シナプス機能を増強するためのｈｄａｃ２−ｓｐ３複合体の標的化
CN101677978B (zh) 矫正骨吸收和骨形成失调的方法及其试剂盒和组合物
Guzik-Kornacka et al. Blocking the Nogo-A Signaling Pathway to Promote Regeneration and Plasticity After Spinal Cord Injury and Stroke
ES2967696T3 (es) Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios
CN121816183A (zh) 治疗轻度认知障碍的治疗剂组合物以及联合疗法的应用方法
Fernandez et al. P. 14.9 Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-tRNA synthetase-induced myositis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140910

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160530